Christopher Mallow
A5004725461- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- COVID-19 Clinical Research Studies
- Influenza Virus Research Studies
- Lung Cancer Diagnosis and Treatment
- Respiratory viral infections research
- Tracheal and airway disorders
- Viral gastroenteritis research and epidemiology
- Respiratory Support and Mechanisms
- COVID-19 epidemiological studies
- Airway Management and Intubation Techniques
- Atomic and Subatomic Physics Research
- Pleural and Pulmonary Diseases
- Intensive Care Unit Cognitive Disorders
- Pneumonia and Respiratory Infections
- Congenital Diaphragmatic Hernia Studies
- Neonatal Respiratory Health Research
- Voice and Speech Disorders
- Hepatitis B Virus Studies
- Surgical Simulation and Training
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Venous Thromboembolism Diagnosis and Management
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Sleep and Work-Related Fatigue
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
University of Miami
2021-2025
Hennepin County Medical Center
2021-2024
Baystate Medical Center
2021-2024
Intermountain Medical Center
2021-2024
Vanderbilt University Medical Center
2021-2024
Baylor Scott & White Medical Center - Temple
2022-2024
Atrium Health Wake Forest Baptist
2021-2024
Yale University
2024
Baylor University Medical Center
2022-2024
Intermountain Healthcare
2024
A comprehensive understanding of the benefits COVID-19 vaccination requires consideration disease attenuation, determined as whether people who develop despite have lower severity than unvaccinated people.
To characterize the clinical severity of covid-19 associated with alpha, delta, and omicron SARS-CoV-2 variants among adults admitted to hospital compare effectiveness mRNA vaccines prevent admissions related each variant.
Data are not complete for all characteristics in the table; denominators
Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated hospitalizations (1-4) measured shortly after vaccination; longer follow-up is needed to assess durability protection. In an evaluation at 21 hospitals in 18 states, the duration mRNA vaccine (Pfizer-BioNTech or Moderna) (VE) was assessed among adults aged ≥18 years. Among 3,089 hospitalized (including 1,194 COVID-19 case-patients and 1,895 non-COVID-19 control-patients), median age 59 years,...
COVID-19 mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) are effective at preventing COVID-19-associated hospitalization (1-3). However, how well protect against the most severe outcomes of these hospitalizations, including invasive mechanical ventilation (IMV) or death is uncertain. Using a case-control design, vaccine effectiveness (VE) IMV in-hospital was evaluated among adults aged ≥18 years hospitalized 21 U.S. medical centers during March 11, 2021-January 24, 2022....
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination coverage increases in the United States, there is a need to understand real-world effectiveness against disease 2019 (COVID-19) and among people at increased risk for poor outcomes.In multicenter case-control analysis of US adults hospitalized March 11-May 5, 2021, we evaluated vaccine prevent COVID-19 hospitalizations by comparing odds prior with messenger RNA (mRNA) (Pfizer-BioNTech or Moderna) between cases...
Monovalent COVID-19 mRNA vaccines, designed against the ancestral strain of SARS-CoV-2, successfully reduced COVID-19-related morbidity and mortality in United States globally (1,2). However, vaccine effectiveness (VE) COVID-19-associated hospitalization has declined over time, likely related to a combination factors, including waning immunity and, with emergence Omicron variant its sublineages, immune evasion (3). To address these on September 1, 2022, Advisory Committee Immunization...
COVID-19 mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) provide protection against infection with SARS-CoV-2, the virus that causes COVID-19, are highly effective COVID-19-associated hospitalization among eligible persons who receive 2 doses (1,2). However, vaccine effectiveness (VE) immunocompromising conditions* is lower than immunocompetent (2), VE declines after several months all (3). On August 12, 2021, Food Drug Administration (FDA) issued an emergency use...
Abstract Objective To compare the effectiveness of a primary covid-19 vaccine series plus booster doses with alone for prevention hospital admission omicron related in United States. Design Multicenter observational case-control study test negative design. Setting Hospitals 18 US states. Participants 4760 adults admitted to one 21 hospitals acute respiratory symptoms between 26 December 2021 and 30 June 2022, period when variant was dominant. included 2385 (50.1%) patients laboratory...
On June 21, 2023, CDC's Advisory Committee on Immunization Practices recommended respiratory syncytial virus (RSV) vaccination for adults aged ≥60 years, offered to individual using shared clinical decision-making.Informed use of these vaccines requires an understanding RSV disease severity.To characterize RSV-associated severity, 5,784 years hospitalized with acute illness and laboratory-confirmed RSV, SARS-CoV-2, or influenza infection were prospectively enrolled from 25 hospitals in 20...
In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5)COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease.However, few estimates of vaccine effectiveness (VE) against medically attended illness are available.This analysis evaluated VE an COVID-19 dose COVID-19-associated emergency department (ED) or urgent care (UC) encounters and hospitalization among immunocompetent adults ≥18...
In the United States, annual influenza vaccination is recommended for all persons aged ≥6 months.Using data from four vaccine effectiveness (VE) networks during 2023-24 season, interim VE was estimated among patients months with acute respiratory illness-associated medical encounters using a test-negative casecontrol study design.Among children and adolescents 6 months-17 years, against influenza-associated outpatient visits ranged 59% to 67% hospitalization 52% 61%.Among adults ≥18 33% 49%...
Importance On June 21, 2023, the Centers for Disease Control and Prevention recommended first respiratory syncytial virus (RSV) vaccines adults aged 60 years older using shared clinical decision-making. Understanding severity of RSV disease in can help guide this Objective To describe among hospitalized with compare it COVID-19 influenza by vaccination status. Design, Setting, Participants In cohort study, 18 admitted to hospital acute illness laboratory-confirmed RSV, SARS-CoV-2, or...
COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2024-2025 vaccine, which targets Omicron JN.1 JN.1-derived sublineages. Interim effectiveness of vaccines was estimated against COVID-19-associated emergency department (ED) or urgent care (UC) visits September 2024-January 2025 among adults ≥18 years in one...
ABSTRACT Background As SARS-CoV-2 vaccination coverage increases in the United States (US), there is a need to understand real-world effectiveness against severe Covid-19 and among people at increased risk for poor outcomes. Methods In multicenter case-control analysis of US adults hospitalized March 11 - May 5, 2021, we evaluated vaccine prevent hospitalizations by comparing odds prior with an mRNA (Pfizer-BioNTech or Moderna) between cases hospital-based controls who tested negative...
The SARS-CoV-2 Omicron variant (B.1.1.529 or BA.1) became predominant in the United States by late December 2021 (1). BA.1 has since been replaced emerging lineages BA.2 (including BA.2.12.1) March 2022, followed BA.4 and BA.5, which have accounted for a majority of infections June 2022 Data on effectiveness monovalent mRNA COVID-19 vaccines against BA.4/BA.5-associated hospitalizations are limited, their interpretation is complicated waning vaccine-induced immunity (2-5). Further, with...
As of April 2023, the COVID-19 pandemic has resulted in 1.1 million deaths United States, with approximately 75% occurring among adults aged ≥65 years (1). Data on durability protection provided by monovalent mRNA vaccination against critical outcomes are limited beyond Omicron BA.1 lineage period (December 26, 2021-March 2022). In this case-control analysis, effectiveness 2-4 vaccine doses was evaluated COVID-19-associated invasive mechanical ventilation (IMV) and in-hospital death...
Abstract Introduction Understanding the changing epidemiology of adults hospitalized with coronavirus disease 2019 (COVID-19) informs research priorities and public health policies. Methods Among (≥18 years) laboratory-confirmed, acute COVID-19 between 11 March 2021, 31 August 2022 at 21 hospitals in 18 states, those during severe respiratory syndrome 2 (SARS-CoV-2) Omicron-predominant period (BA.1, BA.2, BA.4/BA.5) were compared to from earlier Alpha- Delta-predominant periods. Demographic...
This study evaluates the effectiveness of respiratory syncytial virus vaccine against hospitalization for acute illness among US adults aged 60 years and older.
Assessing variant-specific COVID-19 vaccine effectiveness (VE) and severity can inform public health risk assessments decisions about composition. BA.2.86 its descendants, including JN.1 (referred to collectively as "JN lineages"), emerged in late 2023 exhibited substantial divergence from co-circulating XBB lineages.
Annual influenza vaccination is recommended for all persons aged ≥6 months in the United States. Interim vaccine effectiveness (VE) was calculated among patients with acute respiratory illness-associated outpatient visits and hospitalizations from four VE networks during 2024-25 season (October 2024-February 2025). Among children adolescents <18 years, against any 32%, 59%, 60% setting three networks, influenza-associated hospitalization 63% 78% two networks. adults ≥18 36% 54% 41% 55%...
The study objective was to evaluate 2- and 3-dose coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness (VE) in preventing COVID-19 hospitalization among adult solid organ transplant (SOT) recipients.
Influenza circulation during the 2022-2023 season in United States largely returned to pre-coronavirus disease 2019 (COVID-19)-pandemic patterns and levels. A(H3N2) viruses were detected most frequently this season, predominately clade 3C.2a1b.2a, a close antigenic match vaccine strain.
To characterize the clinical severity of COVID-19 caused by Omicron, Delta, and Alpha SARS-CoV-2 variants among hospitalized adults to compare effectiveness mRNA vaccines prevent hospitalizations each variant.A case-control study 11,690 adults.Twenty-one hospitals across United States.This included 5728 cases with 5962 controls without COVID-19. Cases were classified into variant groups based on viral whole genome sequencing, if sequencing did not reveal a lineage, predominant circulating at...